Clinical Trials Directory

Trials / Unknown

UnknownNCT01637675

Efficacy and Safety Study of Sodium Tanshinone IIA Sulfonate on Pulmonary Hypertension

Clinical Study of Effects of Sodium Tanshinone IIA Sulfonate on Pulmonary Hypertension

Status
Unknown
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
90 (estimated)
Sponsor
The First Affiliated Hospital of Guangzhou Medical University · Academic / Other
Sex
All
Age
15 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Sodium tanshinone IIA sulfonate (STS) is a water-soluble derivative of tanshinone IIA isolated as the main pharmacologically active natural compound from a traditional Chinese herbal medicine,the dried root of Salvia miltiorrhiza Bunge known as Danshen. Danshen has been known for the function of improving body functions such as activating blood circulation and removing blood stasis according to the theory of traditional Chinese medicine. Danshen and its various formula products including STS have been long-time widely used in oriental countries, especially China to treat various inflammatory and cardiovascular diseases for its pharmacological actions, including vasodilatation, anticoagulation, anti-inflammation, and free radical scavenging,with negligible adverse effects observed. The investigator's objective is to evaluate whether STS exhibits beneficial effects on pulmonary hypertension. This is a randomized, controlled, multicentre clinical trial study. 90 patients with pulmonary hypertension will be enrolled in this study.

Conditions

Interventions

TypeNameDescription
DRUG20 mg sildenafil citrate by mouth20 mg sildenafil citrate tablets by mouth three times a day for 8 weeks
DRUGsodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouthsodium Tanshinone IIA sulfonate injection 80 mg diluted with 5% glucose solution(0.9% sodium chloride injection will also be permitted if necessary) 250ml iv drip once a day for 8 weeks,as well as 20mg sildenafil citrate tablets by mouth three times a day for the same duration of treatment

Timeline

Start date
2013-05-01
Primary completion
2014-12-01
Completion
2014-12-01
First posted
2012-07-11
Last updated
2014-03-31

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT01637675. Inclusion in this directory is not an endorsement.